January 15th 2025
Building on a previous report that revealed corrupt business practices among the big 3 PBMs, a second interim report finds that PBMs heightened prices for important specialty generic drugs to increase their profit margins.
Rheumatoid Arthritis (RA): More Than a Disease of the Joints
June 1st 2017Kevin Mange, MD, MSCE, head of North America Medical Immunology at Sanofi, provides a comprehensive overview of the considerations in the treatment of rheumatoid arthritis, which carries comorbidities that affect multiple organ systems.